SCHEMBL410769

SCHEMBL410769

OCc1ccccc1-c1cc(Cl)cc(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDCD1 Q15116 1/20 0.44
CD274 Q9NZQ7 1/20 0.44
PDK2 Q15119 4/20 0.44
DPP4 P27487 1/20 0.41
HSD17B3 P37058 1/20 0.40
CYP2C19 P33261 1/20 0.40
PTPRC P08575 1/20 0.40
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
KMT2A Q03164 1/20 0.39
ADORA2A P29274 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
BRD4 O60885 1/20 0.37
BRD9 Q9H8M2 1/20 0.37
BAZ2B Q9UIF8 1/20 0.37
BAZ2A Q9UIF9 1/20 0.37
SLC6A4 P31645 1/20 0.36
CHRM1 P11229 2/20 0.36
CHRM3 P20309 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14128373 0.88 ADORA2A (0.39) PDCD1CD274PDK2DPP4HSD17B3
SCHEMBL1206479 0.84 CNR2 (0.51) PDCD1CD274CNR1CNR2
SCHEMBL1497158 0.83 CYP2C19 (0.53) PDCD1CD274PDK2DPP4HSD17B3
SCHEMBL1207162 0.82 PDCD1 (0.50) PDCD1CD274PDK2HSD17B3CYP2C19
SCHEMBL30826353 0.78 PDCD1 (0.65) PDCD1CD274PDK2DPP4KMT2A
SCHEMBL117091 0.78 PDCD1 (0.65) PDCD1CD274PDK2DPP4KMT2A
SCHEMBL13802493 0.78 PTGER1 (0.49) CHRM1CHRM3
SCHEMBL2391279 0.77 CYP2C19 (0.48) CYP2C19PTPRCCNR1CNR2KMT2A
Biphenyl SCHEMBL11301140 0.76 PDCD1 (0.63) PDCD1CD274PDK2DPP4KMT2A
Hydrogen Sulfide SCHEMBL27879829 0.76 PDCD1 (0.63) PDCD1CD274PDK2DPP4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2325651-B1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding SCRIPPS RESEARCH INST (US) 2014-10-08 EP disclosed
US-20140134753-A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES THE SCRIPPS RESEARCH INSTITUTE (US) 2014-05-15 US disclosed
US-20140134753-A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES THE SCRIPPS RESEARCH INSTITUTE (US) 2014-05-15 US disclosed
US-20140134753-A1 METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES THE SCRIPPS RESEARCH INSTITUTE (US) 2014-05-15 US disclosed
US-8653119-B2 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE (US) 2014-02-18 US disclosed
US-8653119-B2 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE (US) 2014-02-18 US disclosed
US-8653119-B2 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE (US) 2014-02-18 US disclosed
US-20120309835-A1 METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES REVISION THERAPEUTICS, INC. (US) 2012-12-06 US disclosed
US-20120288568-A1 METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION REVISION THERAPEUTICS, INC. (US) 2012-11-15 US disclosed
US-20120202885-A1 METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES REVISION THERAPEUTICS, INC. (US) 2012-08-09 US disclosed
US-7214695-B2 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding THE SCRIPPS RESEARCH INSTITUTE (US) 2007-05-08 US disclosed
US-20070078186-A1 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE 2007-04-05 US disclosed
US-20070078186-A1 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE 2007-04-05 US disclosed
US-20070078186-A1 Methods for treating transthyretin amyloid diseases THE SCRIPPS RESEARCH INSTITUTE 2007-04-05 US disclosed
US-20070015827-A1 Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation SYTERA, INC. (US) 2007-01-18 US disclosed
WO-2007008821-A2 METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION SIRION THERAPEUTICS, INC. (US) 2007-01-18 WO disclosed
US-20060135460-A1 Methods, assays and compositions for treating retinol-related diseases SYTERA, INC. (US) 2006-06-22 US disclosed
WO-2006063128-A2 METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES SIRION THERAPEUTICS, INC. (US) 2006-06-15 WO disclosed
US-20060057644-A1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding SCRIPPS RESEARCH INSTITUTE, THE 2006-03-16 US disclosed
US-20040152140-A1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding THE SCRIPPS RESEARCH INSTITUTE 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120288568-A1 METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA SERUM RETINOL, SERUM RETINOL BINDING PROTEIN (RBP), AND/OR SERUM RETINOL-RBP MODULATION RBP1, RBP4, ALDH1A2 PDCD1 2560/4885CD274 2256/4885PDK2 1677/4885
US-20070078186-A1 Methods for treating transthyretin amyloid diseases TTR, TTPA, PRNP PDCD1 3970/4885CD274 4732/4885PDK2 3342/4885
US-20120309835-A1 METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES RBP1, RBP4, TTR PDCD1 4356/4885CD274 4486/4885PDK2 3786/4885
US-20060135460-A1 Methods, assays and compositions for treating retinol-related diseases RBP1, RBP4, TTR PDCD1 4356/4885CD274 4486/4885PDK2 3786/4885
US-20070015827-A1 Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation RBP1, RBP4, ALDH1A2 PDCD1 2560/4885CD274 2256/4885PDK2 1677/4885
US-20120202885-A1 METHODS, ASSAYS AND COMPOSITIONS FOR TREATING RETINOL-RELATED DISEASES RBP1, RBP4, TTR PDCD1 4356/4885CD274 4486/4885PDK2 3786/4885
US-20060057644-A1 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding TTR, TTPA, PRNP PDCD1 3541/4885CD274 4549/4885PDK2 3844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.